These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Incidence of Acute Endophthalmitis after Intravitreal Antivascular Endothelial Growth Factor Injection in Age-related Macular Degeneration. Seong HJ; Park YM; Kim J; Son KJ; Chung EJ Korean J Ophthalmol; 2022 Oct; 36(5):435-442. PubMed ID: 35989065 [TBL] [Abstract][Full Text] [Related]
11. Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis. Hernandez L; Lanitis T; Cele C; Toro-Diaz H; Gibson A; Kuznik A J Manag Care Spec Pharm; 2018 Jul; 24(7):608-616. PubMed ID: 29952707 [TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of first-line anti-vascular endothelial growth factor treatment patterns in wet age-related macular degeneration. Johnston SS; Wilson K; Huang A; Smith D; Varker H; Turpcu A Adv Ther; 2013 Dec; 30(12):1111-27. PubMed ID: 24310208 [TBL] [Abstract][Full Text] [Related]
13. [Neovascular recurrences in 42 treatment-naive eyes with neovascular age-related macular degeneration (AMD) followed for over 2 years]. Bodénès F; Massé H; Lebreton O; Weber M J Fr Ophtalmol; 2021 May; 44(5):626-631. PubMed ID: 33840491 [TBL] [Abstract][Full Text] [Related]
16. Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia. Skelly A; Carius HJ; Bezlyak V; Chen FK Adv Ther; 2017 Dec; 34(12):2585-2600. PubMed ID: 29164480 [TBL] [Abstract][Full Text] [Related]
17. Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration. Munk MR; Ceklic L; Ebneter A; Huf W; Wolf S; Zinkernagel MS Acta Ophthalmol; 2016 Dec; 94(8):e757-e764. PubMed ID: 27417506 [TBL] [Abstract][Full Text] [Related]
18. Baseline characteristics and progression of neovascular age-related macular degeneration in patients receiving over 60 intravitreal injections of anti-vascular endothelial growth factor. Prahs P; Brandl C; Helbig H; Volz C Rom J Ophthalmol; 2023; 67(3):260-266. PubMed ID: 37876508 [No Abstract] [Full Text] [Related]
19. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial. Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124 [TBL] [Abstract][Full Text] [Related]
20. Cost of Ranibizumab Port Delivery System vs Intravitreal Injections for Patients With Neovascular Age-Related Macular Degeneration. Sood S; Mandell J; Watane A; Friedman S; Parikh R JAMA Ophthalmol; 2022 Jul; 140(7):716-723. PubMed ID: 35708679 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]